Lorus Therapeutics announced recently that it has initiated a phase III trial to evaluate the macrophage activator Virulizin for the treatment of advanced pancreatic cancer. The company will present the results of this trial to the US Food and Drug Administration (FDA) in a new drug application at the completion of the study.
Lorus Therapeutics announced recently thatit has initiated a phase III trial to evaluate the macrophage activatorVirulizin for the treatment of advanced pancreatic cancer. The company willpresent the results of this trial to the US Food and Drug Administration (FDA)in a new drug application at the completion of the study.
Study Protocol
The double-blind randomized clinical trial will be conducted atapproximately 40 medical centers in North America with the goal of enrolling 350patients with advanced pancreatic cancer. Patients will be randomized to receiveeither gemcitabine (Gemzar) or gemcitabine in combination with Virulizin.Patients who fail or become refractory to gemcitabine will be treated withfluorouracil (5-FU) or 5-FU in combination with Virulizin.
"This final stage of Virulizin clinical testing ispredicated on an ongoing clinical database of solid efficacy and safetydata," said Dr. Jim A. Wright, chief executive officer at Lorus. "Weendeavor to provide pancreatic cancer patients with increased survival coupledwith improved quality of life through the availability of a promisingtherapeutic approach with little or no toxicity.
Trial History
In a meta-analysis of three earlier phase I/II trials,Virulizin proved to be well-tolerated, increased the survival rate of patients,and maintained their quality of life. Preclinical data demonstrated that theimmunotherapeutic agent exhibited strong antitumor activity in a variety ofhuman tumor models. For example, tumors resistant to treatment with gemcitabineremained responsive to Virulizin.
An estimated 32,300 new cases of pancreatic cancer are diagnosedin North America each year. Of these, approximately 32,000 are expected toresult in death.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers
November 7th 2023Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.